Company Profile
Inflarx NV Stock Price, News & Analysis
- Ticker:
- IFRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Germany and listed in the U
Stock performance
1.72 USD (-2.82%)
Close
Last updated: August 6, 2026
320M USD
Market cap
Why the stock is moving
Following the latest company update, “InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones”, IFRX closed down 2.82% at $1.72 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Complement-Targeted Immunology
InflaRx develops anti-inflammatory therapies that inhibit the complement C5a pathway. Its portfolio includes an oral C5a receptor inhibitor and an antibody against C5a.
Izicopan
Izicopan is an oral C5aR inhibitor designed for differentiated chemistry, metabolic properties and safety. Phase 2a results in hidradenitis suppurativa and chronic spontaneous urticaria support further development in inflammatory and immunologic diseases.
Hidradenitis Suppurativa Strategy
In hidradenitis suppurativa, izicopan produced reductions in abscesses, nodules, draining tunnels and pain over a short treatment period. InflaRx is preparing a Phase 2b program and discussing the development path with the FDA.
Vilobelimab and GOHIBIC
Vilobelimab is an anti-C5a antibody authorized or approved under the GOHIBIC brand for selected critically ill COVID-19 patients. The company has also studied it in pyoderma gangrenosum, but further development in that indication would likely require a partner.
Future catalysts
Completion of FDA communications regarding Phase 2b readiness for izicopan in hidradenitis suppurativa.
Izicopan pharmacokinetic bridging study in China planned during 2026 to enable additional proof-of-concept studies.
Recent news
- 01
- 02
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
Source: Inflarx NV
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Inflarx NV (IFRX)?
Inflarx NV (IFRX) most recently closed at 1.72 USD, a -2.82% move versus the previous session.
What is the market cap of Inflarx NV (IFRX)?
Inflarx NV currently has a market capitalization of 320M USD on BioPharmSignal.
What does Inflarx NV do?
Complement-Targeted Immunology InflaRx develops anti-inflammatory therapies that inhibit the complement C5a pathway. Its portfolio includes an oral C5a receptor inhibitor and an antibody against C5a. Izicopan Izicopan is an oral C5aR inhibitor designed for differentiated chemistry, metabolic properties and safety. Phase 2a results in hidradenitis...
On which exchange is IFRX stock listed?
Inflarx NV (IFRX) is associated with NASDAQ, Germany and listed in the U, Biopharma.
What is COVID-19?
Vilobelimab and GOHIBIC Vilobelimab is an anti-C5a antibody authorized or approved under the GOHIBIC brand for selected critically ill COVID-19 patients.
Which conditions is Inflarx NV targeting with COVID-19?
Inflarx NV is associated with immunology, metabolic disease based on its company overview and current catalyst commentary.
How does Inflarx NV describe recent progress with COVID-19?
Completion of FDA communications regarding Phase 2b readiness for izicopan in hidradenitis suppurativa. Izicopan pharmacokinetic bridging study in China planned during 2026 to enable additional proof-of-concept studies.
What is proof-of-concept?
Izicopan pharmacokinetic bridging study in China planned during 2026 to enable additional proof-of-concept studies.